Ejc Supplements最新文献

{"title":"^99mTc/¹²³I Dual-Radionuclide Correction for Self-Scatter, Down-Scatter, and Tailing Effect for a CZT SPECT with Varying Tracer Distributions.","authors":"Alexandre F Velo, Peng Fan, Huidong Xie, Xiongchao Chen, Nabil Boutagy, Attila Feher, Albert J Sinusas, Michael Ljungberg, Chi Liu","doi":"10.1109/trpms.2023.3297443","DOIUrl":"10.1109/trpms.2023.3297443","url":null,"abstract":"<p><p>SPECT systems distinguish radionuclides by using multiple energy windows. For CZT detectors, the energy spectrum has a low energy tail leading to additional crosstalk between the radionuclides. Previous work developed models to correct the scatter and crosstalk for CZT-based dedicated cardiac systems with similar ^99mTc/¹²³I tracer distributions. These models estimate the primary and scatter components by solving a set of equations employing the MLEM approach. A penalty term is applied to ensure convergence. The present work estimates the penalty term for any ^99mTc/¹²³I activity level. An iterative approach incorporating Monte Carlo into the iterative image reconstruction loops was developed to estimate the penalty terms. We used SIMIND and XCAT phantoms in this study. Distribution of tracers in the myocardial tissue and blood pool were varied to simulate a dynamic acquisition. Evaluations of the estimated and the real penalty terms were performed using simulations and large animal data. The myocardium to blood pool ratio was calculated using ROIs in the myocardial tissue and the blood pool for quantitative analysis. All corrected images yielded a good agreement with the gold standard images. In conclusion, we developed a CZT crosstalk correction method for quantitative imaging of ^99mTc/¹²³I activity levels by dynamically estimating the penalty terms.</p>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"1 1","pages":"839-850"},"PeriodicalIF":4.6,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78505336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-COVID-19 Disparities in Telemedicine Use Among Louisiana Medicaid Beneficiaries.","authors":"Kevin Callison, Andrew Anderson, Yixue Shao, Thomas A LaVeist, Brigham Walker","doi":"10.1089/tmj.2022.0034","DOIUrl":"10.1089/tmj.2022.0034","url":null,"abstract":"<p><p><b><i>Background:</i></b> <i>We examine trends in telemedicine use by race, geography, and age among Louisiana Medicaid beneficiaries in the months preceding the COVID-19 pandemic.</i> <b><i>Methods:</i></b> <i>Using Louisiana Medicaid claims data from January 2018 through February 2020, we calculated a relative ratio of telemedicine use as the share of telemedicine claims by race, age, and geography and conducted two-sample</i> t<i>-tests.</i> <b><i>Results:</i></b> <i>In 2018, White beneficiaries used telemedicine at a relative ratio of 1.92 compared with Black beneficiaries (</i>p <i>< 0.001) and 2.02 compared with Hispanic beneficiaries (</i>p <i>< 0.001). Rural beneficiaries used telemedicine at a relative ratio of 1.27 (</i>p <i>< 0.001) compared with urban beneficiaries. Children and adolescents used telemedicine at a higher rate than other age groups. Racial and geographic disparities narrowed in the first months of 2020.</i> <b><i>Conclusions:</i></b> <i>Telemedicine use in Louisiana Medicaid was low but growing before the pandemic with narrowing disparities by race and geography and emerging disparities by age.</i></p>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"8 1","pages":""},"PeriodicalIF":4.7,"publicationDate":"2022-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78484182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The importance of basal-temporal white matter to pre- and post-surgical naming ability in temporal lobe epilepsy.","authors":"Erik Kaestner, Alena Stasenko, Sharona Ben-Haim, Jerry Shih, Brianna M Paul, Carrie R McDonald","doi":"10.1016/j.nicl.2022.102963","DOIUrl":"10.1016/j.nicl.2022.102963","url":null,"abstract":"<p><strong>Objective: </strong>Emerging research highlights the importance of basal-temporal cortex, centered on the fusiform gyrus, to both pre-surgical naming ability and post-surgical naming outcomes in temporal lobe epilepsy (TLE). In this study, we investigate whether integrity of the white matter network that interconnects this basal region to the distributed language network affects naming ability and risk for post-surgical naming decline.</p><p><strong>Methods: </strong>Patients with drug-resistant TLE were recruited from two epilepsy centers in a prospective longitudinal study. The pre-surgical dataset included 50 healthy controls, 47 left TLE (L-TLE), and 41 right TLE (R-TLE) patients. All participants completed pre-surgical T1- and diffusion-weighted MRI (dMRI), as well as neuropsychological tests of auditory and visual naming. Nineteen L-TLE and 18 R-TLE patients underwent anterior temporal lobectomy (ATL) and also completed post-surgical neuropsychological testing. Pre-surgical fractional anisotropy (FA) of the white matter directly beneath the fusiform neocortex (i.e., superficial white matter; SWM) and of deep white matter tracts with connections to the basal-temporal cortex [inferior longitudinal fasciculus (ILF) and inferior frontal occipital fasciculus (IFOF)] was calculated. Clinical variables, hippocampal volume, and FA of each white matter tract or region were examined in linear regressions with naming scores, or change in naming scores, as the primary outcomes.</p><p><strong>Results: </strong>Pre-surgically, higher FA in the bilateral ILF, bilateral IFOF, and left fusiform SWM was associated with better visual and auditory naming scores (all ps < 0.05 with FDR correction). In L-TLE, higher pre-surgical FA was also associated with less naming decline post-surgically, but results varied across tracts. When including only patients with typical language dominance, only integrity of the right fusiform SWM was associated with less visual naming decline (p = .0018).</p><p><strong>Discussion: </strong>Although a broad network of white matter network matter may contribute to naming ability pre-surgically, the reserve capacity of the contralateral (right) fusiform SWM may be important for mitigating visual naming decline following ATL in L-TLE. This shows that the study of the structural network interconnecting the basal-temporal region to the wider language network has implications for understanding both pre- and post-surgical naming in TLE.</p>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"5 1","pages":"102963"},"PeriodicalIF":3.4,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78408624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study","authors":"Matthew Glover ,&nbsp;Martyn Caplin ,&nbsp;Oscar R. Leeuwenkamp ,&nbsp;Louise Longworth","doi":"10.1016/j.ejcsup.2021.06.003","DOIUrl":"10.1016/j.ejcsup.2021.06.003","url":null,"abstract":"<div><h3>Aim</h3><p>To evaluate the cost-effectiveness of [¹⁷⁷Lu]Lu-DOTA-TATE versus relevant comparators for the treatment of neuroendocrine tumours located in the gastrointestinal tract (GI-NETs) and the pancreas (P-NETs).</p></div><div><h3>Materials and methods</h3><p>A three-state partitioned survival model was developed to perform a cost-utility analysis of [¹⁷⁷Lu]Lu-DOTA-TATE versus standard of care (high dose Octreotide LAR), everolimus and sunitinib. Effectiveness data for SoC, everolimus and sunitinib were obtained from published Kaplan–Meier survival curves. Given a lack of head-to-head effectiveness data, matching adjusted indirect comparisons (MAICs) were performed to population-adjust [¹⁷⁷Lu]Lu-DOTA-TATE survival data based on prognostic factors and derive estimates of relative effectiveness. Health state utilities were estimated from real-world evidence. Drug acquisition costs were taken from nationally published sources (BNF, NICE), and administration costs were based on treatment protocols in [¹⁷⁷Lu]Lu-DOTA-TATE studies, combined with nationally published unit costs (PSSRU, DoH reference costs). Incidence of adverse events were estimated using published sources. A discount rate of 3.5% was applied to both utilities and costs, and deterministic and probabilistic sensitivity analyses were performed. Costs were included from an NHS perspective and presented in 2017/18 GBP (and PPP Euros for base case).</p></div><div><h3>Results</h3><p>In GI-NETs, the incremental cost-effectiveness ratio (ICER) of [¹⁷⁷Lu]Lu-DOTA-TATE compared to SoC and everolimus was £26,528 (€27,672) and £24,145 (€25,186) per QALY, respectively. In P-NETs, the ICER of [¹⁷⁷Lu]Lu-DOTA-TATE compared to SoC was £22,146 (€23,101) or £28,038 (€29,251) dependent on matched population, and £21,827 (€22,766) and £15,768 (€16,445) compared to everolimus and sunitinib, respectively.</p></div><div><h3>Conclusions</h3><p>At a willingness to pay threshold of £30,000, [¹⁷⁷Lu]Lu-DOTA-TATE is likely to be a cost-effective treatment option for GI-NET and P-NET patients versus relevant treatment comparators (NHS perspective).</p></div>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"16 ","pages":"Pages 14-23"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/f0/main.PMC8591195.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39606055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?","authors":"Martyn E. Caplin","doi":"10.1016/j.ejcsup.2021.06.001","DOIUrl":"10.1016/j.ejcsup.2021.06.001","url":null,"abstract":"","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"16 ","pages":"Pages 1-4"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0b/0c/main.PMC8591180.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39606052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours","authors":"Mohid S. Khan ,&nbsp;Elaine Stamp ,&nbsp;Cormac Sammon ,&nbsp;Tessa Brabander ,&nbsp;Wouter W. de Herder ,&nbsp;Marianne E. Pavel","doi":"10.1016/j.ejcsup.2021.06.002","DOIUrl":"10.1016/j.ejcsup.2021.06.002","url":null,"abstract":"<div><p>Head-to-head comparisons of the efficacy of treatments for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) have not yet been reported. This study used a series of matching-adjusted indirect comparisons to indirectly compare the effectiveness of [¹⁷⁷Lu]Lu-DOTA-TATE to everolimus, sunitinib and best supportive care (BSC) for extending progression-free survival and overall survival in patients with advanced, unresectable gastrointestinal (GI)-NETs and P-NETs. The results of the main analysis suggest that after accounting for differences in key prognostic variables, the hazard of progression was 62% (hazard ratio [HR], 0.38; confidence interval [CI]₉₅ 0.25–0.58) and 65% (HR 0.35 CI₉₅ 0.21–0.59) lower in patients with GI-NETs treated with [¹⁷⁷Lu]Lu-DOTA-TATE than in those treated with everolimus and BSC, respectively. Similarly, the hazard of progression was 64% (HR 0.36 CI₉₅ 0.18–0.70), 54% (HR 0.46 CI₉₅ 0.30–0.71) and 79–87% (HR 0.21 CI₉₅ 0.13–0.32; HR 0.13 CI₉₅ 0.08–0.22) lower in patients with P-NET treated with [¹⁷⁷Lu]Lu-DOTA-TATE than in those treated with sunitinib, everolimus and BSC, respectively. The hazard of death was 58% (HR 0.42 CI₉₅ 0.25–0.72), 47% (HR 0.53 CI₉₅ 0.33–0.87) and 44–64% (HR 0.56 CI₉₅ 0.36–0.90; HR 0.34 CI₉₅ 0.20–0.57) lower in P-patients with NET treated with [¹⁷⁷Lu]Lu-DOTA-TATE than in those treated with sunitinib, everolimus and BSC, respectively. While our results must be interpreted with caution given the non-randomised nature of the comparisons and the potential for residual confounding, the magnitude of the effect sizes we observe and their consistency across comparators suggest that [¹⁷⁷Lu]Lu-DOTA-TATE may be a more effective treatment option than everolimus, sunitinib and BSC in advanced, unresectable GEP-NETs.</p></div>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"16 ","pages":"Pages 5-13"},"PeriodicalIF":0.0,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a1/94/main.PMC8591206.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39606054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DataLad: distributed system for joint management of code, data, and their relationship.","authors":"Yaroslav O Halchenko, Kyle Meyer, Benjamin Poldrack, Debanjum Singh Solanky, Adina S Wagner, Jason Gors, Dave MacFarlane, Dorian Pustina, Vanessa Sochat, Satrajit S Ghosh, Christian Mönch, Christopher J Markiewicz, Laura Waite, Ilya Shlyakhter, Alejandro de la Vega, Soichi Hayashi, Christian Olaf Häusler, Jean-Baptiste Poline, Tobias Kadelka, Kusti Skytén, Dorota Jarecka, David Kennedy, Ted Strauss, Matt Cieslak, Peter Vavra, Horea-Ioan Ioanas, Robin Schneider, Mika Pflüger, James V Haxby, Simon B Eickhoff, Michael Hanke","doi":"10.21105/joss.03262","DOIUrl":"10.21105/joss.03262","url":null,"abstract":"<p><p>DataLad is a Python-based tool for the joint management of code, data, and their relationship, built on top of a versatile system for data logistics (git-annex) and the most popular distributed version control system (Git). It adapts principles of open-source software development and distribution to address the technical challenges of data management, data sharing, and digital provenance collection across the life cycle of digital objects. DataLad aims to make data management as easy as managing code. It streamlines procedures to consume, publish, and update data, for data of any size or type, and to link them as precisely versioned, lightweight dependencies. DataLad helps to make science more reproducible and FAIR (Wilkinson et al., 2016). It can capture complete and actionable process provenance of data transformations to enable automatic re-computation. The DataLad project (datalad.org) delivers a completely open, pioneering platform for flexible decentralized research data management (RDM) (Hanke, Pestilli, et al., 2021). It features a Python and a command-line interface, an extensible architecture, and does not depend on any centralized services but facilitates interoperability with a plurality of existing tools and services. In order to maximize its utility and target audience, DataLad is available for all major operating systems, and can be integrated into established workflows and environments with minimal friction.</p>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78458307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunotherapies in ovarian cancer","authors":"Elena García-Martínez ,&nbsp;J. Alejandro Pérez-Fidalgo","doi":"10.1016/j.ejcsup.2020.02.002","DOIUrl":"10.1016/j.ejcsup.2020.02.002","url":null,"abstract":"<div><p>Ovarian cancer is the leading cause of death for gynaecological cancer, and new therapies are urgently awaited. Although the presence of tumour-infiltrating lymphocytes has been confirmed to be associated to a better prognosis, immunotherapy is not yet incorporated to the armamentarium in ovarian cancer. This review briefly summarises the strategies that have been tested or are under study for the three different groups of tumours: immune desert, inflamed and immune-excluded ovarian tumours. Finally, a better knowledge of the biology and immune microenvironment is needed for successfully developing new immunotherapy strategies.</p></div>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"15 ","pages":"Pages 87-95"},"PeriodicalIF":0.0,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ejcsup.2020.02.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38645345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare ovarian tumours. Other treatments for ovarian cancer","authors":"Marta Gil-Martin ,&nbsp;Beatriz Pardo ,&nbsp;Maria-Pilar Barretina-Ginesta","doi":"10.1016/j.ejcsup.2019.11.002","DOIUrl":"10.1016/j.ejcsup.2019.11.002","url":null,"abstract":"<div><h3>Aim</h3><p>The description of rare malignant ovarian tumours and the most suitable treatments. Alternative therapies different from intravenous chemotherapy are also explained.</p></div><div><h3>Methods</h3><p>Literature review and ongoing trial information have been used to elaborate this guide.</p></div><div><h3>Results</h3><p>Each ovarian cancer type must be identified and treated properly from diagnostic to surgery, adjuvant treatment and metastatic disease. Hormonotherapy can be useful as an alternative treatment, especially in low-grade ovarian cancer and endometrioid subtype. Tumour characterisation is appropriated for treatment selection when targeted therapy is indicated. MEK inhibitors, tyrosine-kinase inhibitors, EGFR inhibitors, therapies against integrins, antibody–drug conjugates and other strategies are described. Antiangiogenics, PARP inhibitors and immunotherapy are discussed in other parts of this publication.</p></div><div><h3>Conclusion</h3><p>Different ovarian cancer types must receive the appropriated treatment. Alternative therapies may be evaluated beyond the standard therapy, frequently in a clinical trial, and an individualised molecular study may help to find the best treatment.</p></div>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"15 ","pages":"Pages 96-103"},"PeriodicalIF":0.0,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ejcsup.2019.11.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38645346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications","authors":"Ignacio Romero ,&nbsp;Susanna Leskelä ,&nbsp;Belén Pérez Mies ,&nbsp;Andrés Poveda Velasco ,&nbsp;José Palacios","doi":"10.1016/j.ejcsup.2020.02.001","DOIUrl":"10.1016/j.ejcsup.2020.02.001","url":null,"abstract":"<div><p>Ovarian epithelial cancer (OEC) is the most lethal gynecologic malignancy. Despite current chemotherapeutic and surgical options, this high lethality can be attributed to multiple factors, including late-stage presentation. In order to optimize OEC treatment, it is important to highlight that it is composed of five main subtypes: high-grade serous ovarian carcinoma (HGSOC), low-grade serous ovarian carcinoma (LGSOC), endometrioid ovarian carcinoma (EOC), ovarian clear cell carcinoma (CCOC), and mucinous ovarian carcinoma (MOC). These subtypes differ in their precursor lesions, as well as in epidemiological, morphological, molecular and clinical features. OEC is one of the tumours in which most pathogenic germline mutations have been identified. Accordingly, up to 20% OC show alterations in <em>BRCA1/2</em> genes, and also, although with a lower frequency, in other low penetrance genes associated with homologous recombination deficiency (HRD), mismatch repair genes (Lynch syndrome) and <em>TP53</em>. The most important prognostic factor is the 2014 FIGO staging, while older age is also associated with worse survival. HGSOC in all stages and CCC and MOC in advanced stages have the worse prognosis among histological types. Molecular markers have emerged as prognostic factors, particularly mutations in <em>BRCA1/2,</em> which are associated with a better outcome. Regarding treatment, whereas a proportion of HGSOC is sensible to platinum-based treatment and PARP inhibitors due to HRD, the rest of the histological types are relatively chemoresistant. New treatments based in specific molecular alterations are being tested in different histological types. In addition, immunotherapy could be an option, especially for EOC carrying mismatch repair deficiency or <em>POLE</em> mutations.</p></div>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"15 ","pages":"Pages 1-15"},"PeriodicalIF":0.0,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ejcsup.2020.02.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38644500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}